Trial Profile
A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Tecemotide (Primary) ; Goserelin
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors EMD Serono
- 18 Feb 2017 Preliminary results evaluating predictive role of apparent diffusion coefficient on MRI for assessing immunologic impact, presented at the 2017 Genitourinary Cancers Symposium
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.